What are the recommended treatment options for rosacea?

Treatment of Rosacea

Treat rosacea with a phenotype-directed approach: use topical metronidazole, azelaic acid, or ivermectin as first-line therapy for inflammatory lesions; add topical brimonidine or oxymetazoline for persistent erythema; and reserve oral doxycycline 40 mg for moderate-to-severe or treatment-resistant cases. 1, 2

Treatment Algorithm by Clinical Presentation

For Inflammatory Papules and Pustules (Papulopustular Rosacea)

Mild Disease:

• Start with topical monotherapy using one of the following 1, 2:
  • Metronidazole 0.75-1% (once or twice daily): Reduces inflammatory lesions by 65% with improvement visible by week 3 1
  • Azelaic acid 15% gel or foam: Achieves 46-51% treatment success (clear/almost clear) at 12 weeks 1
  • Ivermectin 1% cream (once daily): Superior efficacy with 38-40% achieving clear/almost clear status at 12 weeks 1
  • Encapsulated benzoyl peroxide 5% (E-BPO): Newest option (FDA-approved 2022) with rapid onset by week 2 and 43-50% success rate 1

Moderate-to-Severe Disease:

• Combine topical therapy with oral doxycycline 40 mg once daily (modified-release formulation) 1, 2
• Alternative: Minocycline foam 1.5% topically, which achieved 49-52% success rates in severe cases 1
• For treatment-resistant cases: Consider low-dose oral isotretinoin 3

For Persistent Centrofacial Erythema

Topical vasoconstrictors (these address erythema specifically, not inflammatory lesions) 1, 2:

• Brimonidine tartrate 0.33% gel once daily: 30% achieve 2-grade improvement within 12 hours, with effects visible in 30 minutes 1
• Oxymetazoline HCl 1% cream once daily: Similar efficacy profile 1

Important caveat: 10-20% of patients may experience paradoxical erythema rebound with brimonidine 1

For Telangiectasias and Refractory Erythema

Laser and light-based therapies 2, 4:

• Pulsed dye laser (PDL)
• Intense pulsed light (IPL)
• These are essential for fixed vascular changes that don't respond to anti-inflammatory therapy 1

For Phymatous Changes

Treatment depends on inflammatory activity 2:

• Active/inflamed phyma: Oral isotretinoin or oral antibiotics
• Fibrotic/burnt-out phyma: Surgical interventions (electrosurgery, dermabrasion, surgical resurfacing) 4

Head-to-Head Comparisons: What Works Best?

The evidence shows ivermectin 1% cream is superior to metronidazole 0.75% in direct comparison: 83% vs 73.7% lesion reduction at 16 weeks, with longer time to relapse (115 days vs 85 days) 1. A 2016 network meta-analysis confirmed ivermectin as more effective than both metronidazole and azelaic acid 1.

Combination Therapy Strategy

Multiple features require simultaneous treatment 2:

• Inflammatory lesions + erythema: Combine topical anti-inflammatory (ivermectin/azelaic acid/metronidazole) with topical vasoconstrictor
• Moderate-severe presentations: Topical + oral doxycycline 40 mg
• One study demonstrated additive benefits combining ivermectin 1% cream with brimonidine 0.33% gel without significant side effects 1

If first-line treatment fails, either switch to an alternative first-line option or add an additional first-line agent 2

Maintenance Therapy

Use the minimum treatment necessary to maintain control 2. Treatments should be continued for sufficient duration before switching—this varies by agent but generally means at least 12 weeks for topical therapies based on pivotal trial durations 1.

Ocular Rosacea

Mild cases: Lid hygiene and artificial tears 2

Moderate-severe cases requiring referral to ophthalmology 2, 5:

• Topical antimicrobials (91% response rate)
• Oral antibiotics (89% response rate)
• Cyclosporine ophthalmic emulsion (87% response rate)
• Intense pulsed light (89% partial response)

Essential Adjunctive Measures

All patients require 1, 2:

• Sun protection (SPF 30+)
• Gentle cleansers and moisturizers
• Trigger avoidance (identify and avoid individual triggers)

Key Clinical Pearls

Newer agents to consider: E-BPO 5% offers excellent tolerability with sustained results up to 52 weeks and may reduce treatment-associated irritation compared to traditional benzoyl peroxide 1. Minocycline foam 1.5% (FDA-approved 2020) is particularly effective for moderate-severe disease with low adverse event rates (1.5%) 1.

Common pitfall: Don't use anti-inflammatory therapy alone for persistent erythema—it won't improve fixed vascular changes. These require vasoconstrictors or laser/light therapy 1.

Treatment duration matters: Most topical therapies show efficacy by 3-4 weeks but continue improving through 12 weeks. Don't abandon therapy prematurely 1.